All In Biotech

Drug Trial Radar · NCT07233239

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 26, 2025

Primary completion

Nov 29, 2027

Study completion Nov 29, 2027

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Jazz Pharmaceuticals Research UK Ltd.
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Conditions

  • Focal Seizures

Interventions

  • CBD-OSDrug

    Starting dose of CBD-OS will be administered as per the approved local product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in countable focal seizure frequency compared to baselineTime frame: Baseline up to 16 weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center-Phoenix

    Phoenix, Arizona · Recruiting

  • UC San Diego

    La Jolla, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Serenity Research Center, LLC

    Miami, Florida · Not yet recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Savannah Neurology Specialists

    Savannah, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland · Recruiting

  • Wayne State University

    Detroit, Michigan · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Not yet recruiting

  • Hackensack Meridian Neuroscience Institute at JFK University Medical Center

    Edison, New Jersey · Recruiting

  • Saint Peter's University Hospital

    New Brunswick, New Jersey · Recruiting

  • Boston Children's Health Physicians

    Hawthorne, New York · Recruiting

  • Velocity Clinical Research at Raleigh Neurology

    Raleigh, North Carolina · Recruiting

  • Cincinnati Children's Hospital

    Cincinnati, Ohio · Recruiting

  • University of Cincinnati, Gardner Neuroscience Institute

    Cincinnati, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Not yet recruiting

  • Le Bonheur Children's Hospital

    Memphis, Tennessee · Recruiting

  • Child Neurology & Consultants of Austin

    Austin, Texas · Recruiting

  • ANESC Research

    El Paso, Texas · Recruiting

  • Intermountain Health

    Murray, Utah · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.